CEDRN: Opioid Registry

NCT07466784 | Recruiting

• 2 other identifiers: H24-02162F24-04453
• Study Type: observational
• Target: 7,200
• Locations: 1 country
• Sites: 1

Brief Summary

Unregulated opioids remain a leading driver of preventable mortality and potential years of life lost in Canada. Emergency departments (EDs)-open 24/7 and frequently accessed by people who use drugs-offer critical opportunities to reverse toxicity, mitigate harm, and initiate treatment. Yet, high quality evidence to guide ED care for patients with opioid poisoning and concomitant opioid dependence or opioid use disorder is limited. The investigators aim to establish a pan Canadian registry of patients presenting to EDs with opioid poisoning to generate timely, practice informing evidence. The investigators will create the Canadian Emergency Department Research Network (CEDRN) Opioid Registry across participating EDs nationwide. Using automated screening of electronic health records (EHRs), the investigators will identify consecutive patients of all ages with suspected or confirmed opioid poisoning at their index ED visit. The project's objectives are to establish a pan-Canadian registry of Emergency Department patients presenting with opioid poisoning, harmonize data collection across participating sites, describe variations in patient characteristics, clinical practice and outcomes, and derive a clinical decision rule to predict the risk of dying within 60 days. The expected outcomes include advancing healthcare delivery, improving patient and provider experiences, and enhancing population health and health system sustainability for individuals with opioid poisoning. This research is crucial for addressing the opioid crisis in Canada and has the potential to significantly impact patient care and outcomes.

Conditions

Opioid Withdrawal; Polysubstance Drug Use (Indiscriminate Drug Use); Polysubstance Abuse; Opioid Use Disorder; Opioid Abuse or Dependence

Keywords

Opioid use disorder; Opioid poisoning; CEDRN Opioid Registry; Opioid dependence; polysubstance abuse; polysubstance drug use

Outcome Measures

Primary Outcomes (1)

• Proportion of patients who received opioid agonist therapy (methadone, buprenorphine/naloxone, extended release buprenorphine injection, slow-release oral morphine).

  Number of patients that were administered any of the following types of opioid agonist therapy during their visit to the emergency department.

  From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

Other Outcomes (5)

• Proportion of patients who left against medical advice.

  From date of emergency department arrival date until date and time of first documented "leaving against medical advice" or "leaving without being seen" or other similar terms in patient's medical chart (within the first 72 hours since arrival).

• Proportion of patients hospitalized

  From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

• Proportion of naloxone administration

  From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients presenting to any one of the Canadian Emergency Department Research Network's emergency department, and meeting the inclusion criteria.

You may qualify if:

• All patients who arrive at the emergency department with the following emergency department discharge diagnosis:
• Percocet Overdose
• Oxycontin Overdose
• Oxycodone Overdose
• Opioid Overdose or Intoxication
• Methadone Overdose
• Heroin Overdose
• Fentanyl Overdose
• Codeine Overdose
• Carfentanil Overdose
• Opioid Withdrawal
• All patients who arrive at the emergency department who had the following medication ordered in the present visit or previous hospital visits in the past 2 years:
• Buprenorphine
• Buprenorphine-naloxone
• Methadone - Past ED or IP encounter

Sponsors & Collaborators

• University of British Columbia: lead
• Canadian Institutes of Health Research (CIHR): collaborator

Study Sites (1)

Vancouver General Hospital

Vancouver, British Columbia, V5Z 1M9, Canada

RECRUITING

Related Publications (13)

• Kaczorowski J, Bilodeau J, M Orkin A, Dong K, Daoust R, Kestler A. Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review. Acad Emerg Med. 2020 Nov;27(11):1173-1182. doi: 10.1111/acem.14054. Epub 2020 Jul 28.

  PMID: 32557932 BACKGROUND

• Chen Y, Wang Y, Nielsen S, Kuhn L, Lam T. A systematic review of opioid overdose interventions delivered within emergency departments. Drug Alcohol Depend. 2020 Aug 1;213:108009. doi: 10.1016/j.drugalcdep.2020.108009. Epub 2020 May 23.

  PMID: 32580113 BACKGROUND

• D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1636-44. doi: 10.1001/jama.2015.3474.

  PMID: 25919527 BACKGROUND

• Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, Brasher P, Gill S, Garrod E, Bath M, Kestler A. Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study. J Am Coll Emerg Physicians Open. 2020 Oct 20;1(6):1712-1722. doi: 10.1002/emp2.12289. eCollection 2020 Dec.

  PMID: 33392580 BACKGROUND

• Moe J, Chong M, Zhao B, Scheuermeyer FX, Purssell R, Slaunwhite A. Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis. CMAJ Open. 2021 Mar 17;9(1):E242-E251. doi: 10.9778/cmajo.20200169. Print 2021 Jan-Mar.

  PMID: 33731425 BACKGROUND

• Zhang X, Wang N, Hou F, Ali Y, Dora-Laskey A, Dahlem CH, McCabe SE. Emergency Department Visits by Patients with Substance Use Disorder in the United States. West J Emerg Med. 2021 Aug 19;22(5):1076-1085. doi: 10.5811/westjem.2021.3.50839.

  PMID: 34546883 BACKGROUND

• Beckerleg W, Hudgins J. Substance Use-related Emergency Department Visits and Resource Utilization. West J Emerg Med. 2022 Feb 28;23(2):166-173. doi: 10.5811/westjem.2022.1.53834.

  PMID: 35302449 BACKGROUND

• Mok V, Brebner C, Yap J, Asamoah-Boaheng M, Hutton J, Haines M, Scheuermeyer F, Kawano T, Christenson J, Grunau B. Non-prescription drug-associated out-of-hospital cardiac arrest: Changes in incidence over time and the odds of receiving resuscitation. Resuscitation. 2024 Feb;195:110107. doi: 10.1016/j.resuscitation.2023.110107. Epub 2023 Dec 30.

  PMID: 38160902 BACKGROUND

• Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. Ann Emerg Med. 2021 Sep;78(3):434-442. doi: 10.1016/j.annemergmed.2021.04.023. Epub 2021 Jun 23.

  PMID: 34172303 BACKGROUND

• Gomes T, Kitchen SA, Murray R. Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. JAMA Netw Open. 2021 May 3;4(5):e2112865. doi: 10.1001/jamanetworkopen.2021.12865.

  PMID: 34037734 BACKGROUND

• Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, Tadrous M, Munro C, Antoniou T, Werb D, Wyman J. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA. 2022 Mar 1;327(9):846-855. doi: 10.1001/jama.2022.1271.

  PMID: 35230394 BACKGROUND

• Fischer B

  BACKGROUND

• Nguyen T, Buxton JA. Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework. Int J Drug Policy. 2021 Jul;93:103236. doi: 10.1016/j.drugpo.2021.103236. Epub 2021 Mar 20.

  PMID: 33838990 BACKGROUND

Related Links

• Provincial health officer declares public health emergency
• Federal, provincial, and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses.
• Opioid- and Stimulant-related Harms in Canada
• Illicit Drug Toxicity Type of Drug Data

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Corinne M Hohl, MD, MPH

  University of British Columbia

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jeffrey P Hau, MSc

CONTACT

16048754111; jeffrey.hau@ubc.ca

Vi Ho, MD

CONTACT

6048754111; vi.ho@ubc.ca

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor and Head, Department of Emergency Medicine at UBC

Study Record Dates

• First Submitted: February 20, 2026
• First Posted: March 12, 2026
• Study Start: July 24, 2025
• Primary Completion (Estimated): July 24, 2030
• Study Completion (Estimated): December 31, 2030
• Last Updated: March 12, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)